2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 406

Adults with Juvenile Idiopathic Arthritis Are Not Adults with Rheumatoid Arthritis
Abstract Number: 1008

Advantageous Effect of an Endogenous Retroviral Envelope Protein in Systemic Lupus Erythematosus with Ex Vivo and In Vivo Anti-Inflammatory Potential
Abstract Number: 1968

Adverse Childhood Experiences and Outcomes of Systemic Lupus Erythematosus
Abstract Number: 2658

Adverse Drug Reactions Due to Disease Modifying Drugs in Patients with Rheumatoid Arthritis
Abstract Number: 15

Adverse Events and Persistency of Biologics in Rheumatoid Arthritis Patients with Interstitial Lung Disease
Abstract Number: 1150

Advocacy 101: Engaging Rheumatology Fellows in Health Policy and Advocacy
Abstract Number: 1823

African American and European American SLE Patients with Variable Disease Activity Reveal Distinct Differences in CD4+ T Cell and Monocyte Pathways
Abstract Number: 3041

Age-Related Defects in the Immune System of Patients with GCA
Abstract Number: 2125

Aggrecan Degradation Is Not Just Aggrecan Degradation:a Study of the Neo-Epitopes Tege and Args Released from Cartilage upon Aggrecanase Activity
Abstract Number: 913

Aggregatibacter Actinomycetemcomitans-Induced Hypercitrullination Links Periodontal Infection to Autoimmunity in Rheumatoid Arthritis
Abstract Number: 133

Agreement Between DAS28-ESR, DAS28-CRP, SDAI, CDAI (Simplified/Clinical Disease Activity Index), ACR/EULAR Remission Criteria and Ultrasound Scoring (Naredo-12) in Patients with Rheumatoid Arthritis in Routine Care
Abstract Number: 2936

All-Trans Retinoic Acid Stabilizes Natural T Regulatory Cells Isolated from Patients with Systemic Lupus Erythematosus Under Inflammatory Conditions
Abstract Number: 1211

Allele-Dependent Binding of a Viral Protein to Autoimmune Disease-Associated Genetic Variants
Abstract Number: 203

Allopurinol Dose Escalation and Mortality Among Patients with Gout: A National Propensity-Matched Cohort Study
Abstract Number: 201

Allopurinol Reduces the Risk of Myocardial Infarction (MI) in the Elderly: A Study of Medicare Claims

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].